PE20040452A1 - Pentafluorosulfanilbenzoilguanidinas como inhibidores del nhe - Google Patents

Pentafluorosulfanilbenzoilguanidinas como inhibidores del nhe

Info

Publication number
PE20040452A1
PE20040452A1 PE2003000415A PE2003000415A PE20040452A1 PE 20040452 A1 PE20040452 A1 PE 20040452A1 PE 2003000415 A PE2003000415 A PE 2003000415A PE 2003000415 A PE2003000415 A PE 2003000415A PE 20040452 A1 PE20040452 A1 PE 20040452A1
Authority
PE
Peru
Prior art keywords
benzoyl
compounds
nhe
pentafluorosulfanil
guanidflu
Prior art date
Application number
PE2003000415A
Other languages
English (en)
Inventor
Heinz-Werner Kleemann
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of PE20040452A1 publication Critical patent/PE20040452A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C381/00—Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SE REFIERE A UN COMPUESTOS ACILGUANIDINAS DE FORMULA I Y II DONDE R1 ES H, ALQUILO(C1-C4), ALCOXI(C1-C4), HALOGENO, CN, NR10R1, -O-CH2-CF3, -SOm(CH2)r-CF3, ENTRE OTROS; R2 ES H, HALOGENO, CN, -SO2CH3, -(S0h)z-(CH2)k-CF3, FENILO o O-FENILO SUSTITUIDO O NO, O HETEROARILO SUSTITUIDO O NO, ENTRE OTROS; R3 Y R4 SON INDEPENDIENTEMENTE H O F. SON COMPUESTOS PREFERIDOS: HIDROCLORURO DE-3-PENTAFLUOROSULFANILBENZOILGUANIDINA, N-[2-(4-FLUOROFENOXI)-4-PENTAFLUOROSULFANIL-BENZOIL]GUANIDINA, N-(2-METIL-5-PENTAFLUOROSULFANILBENZOIL)-GUANIDINA, 4-PENTAFLUOROSULFANIL-2-METILBENZOILGUANDINA, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA SU ELABORACION. ESTOS COMPUESTOS INHIBEN EL ANTIPORTER CELULAR SODIO-PROTON (INTERCAMBIADOR Na+/H+, NHE). SON ADECUADOS COMO MEDICAMENTOS ANTIARRITMICOS CON UN COMPONENTE CARDIOPROTECTOR PARA LA PROFILAXIS Y TRATAMIENTO DEL INFARTO, ANGINA DE PECHO. TAMBIEN PREVIENEN LOS PROCESOS PATOFISIOLOGICOS ASOCIADOS CON EL DANO INDUCIDO POR LA ISQUEMIA
PE2003000415A 2002-05-18 2003-04-25 Pentafluorosulfanilbenzoilguanidinas como inhibidores del nhe PE20040452A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10222192A DE10222192A1 (de) 2002-05-18 2002-05-18 Pentafluorsulfuranyl-benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament

Publications (1)

Publication Number Publication Date
PE20040452A1 true PE20040452A1 (es) 2004-08-18

Family

ID=29285565

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000415A PE20040452A1 (es) 2002-05-18 2003-04-25 Pentafluorosulfanilbenzoilguanidinas como inhibidores del nhe

Country Status (29)

Country Link
EP (1) EP1509498B1 (es)
JP (1) JP4383341B2 (es)
KR (1) KR100977676B1 (es)
CN (1) CN100506791C (es)
AR (1) AR040034A1 (es)
AT (1) ATE343563T1 (es)
AU (1) AU2003242531B2 (es)
BR (1) BR0311128A (es)
CA (1) CA2486336C (es)
CY (1) CY1105867T1 (es)
DE (2) DE10222192A1 (es)
DK (1) DK1509498T3 (es)
ES (1) ES2274264T3 (es)
HK (1) HK1076095A1 (es)
HR (1) HRP20041078B1 (es)
IL (2) IL165213A0 (es)
MA (1) MA27277A1 (es)
ME (1) MEP28908A (es)
MX (1) MXPA04011497A (es)
MY (1) MY139310A (es)
NO (1) NO333288B1 (es)
PE (1) PE20040452A1 (es)
PL (1) PL209700B1 (es)
PT (1) PT1509498E (es)
RS (1) RS50772B (es)
RU (1) RU2315752C2 (es)
TW (1) TWI281467B (es)
WO (1) WO2003097591A1 (es)
ZA (1) ZA200408886B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7501440B2 (en) 2003-03-07 2009-03-10 Sanofi-Aventis Deutschland Gmbh Substituted benzoylureidopyridylpiperidine-and-pyrrolidinecarboxylic acid derivatives, processes for preparing them and their use
DE10338554A1 (de) * 2003-08-22 2005-03-31 Aventis Pharma Deutschland Gmbh Pentafluorosulfanylphenyl-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE10353204A1 (de) * 2003-11-13 2005-06-16 Aventis Pharma Deutschland Gmbh Verfahren zur Herstellung von 4-Pentafluorsulfanyl-benzoylguanidinen
OA13285A (en) * 2003-11-13 2007-01-31 Sanofi Aventis Deutschland Pentafluorosulfanyl benzoylguanidines, method for their production, their use as medicaments or diagnostic agents and medicament containing the same.
DE10353205A1 (de) * 2003-11-13 2005-06-16 Aventis Pharma Deutschland Gmbh Ortho-substituierte Pentafluorsulfuranyl-Benzole, Verfahren zu ihrer Herstellung sowie ihre Verwendung als wertvolle Synthese-Zwischenstufen
DE102004043937A1 (de) * 2004-09-11 2006-03-30 Sanofi-Aventis Deutschland Gmbh Ortho-substituierte Pentafluorsulfuranyl-Benzole, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Synthese-Zwischenstufen
DE102004043938A1 (de) * 2004-09-11 2006-03-30 Sanofi-Aventis Deutschland Gmbh Pentafluorosulfanylphenyl-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
KR101136251B1 (ko) * 2007-02-09 2012-04-25 화이자 리미티드 구충제
EP2468722B1 (en) * 2007-03-23 2014-10-01 UBE Industries, Ltd. Process for producing arylsulfur halotetrafluorides
WO2009028514A1 (ja) * 2007-08-28 2009-03-05 Ube Industries, Ltd. ペンタフルオロスルファニルベンゼン化合物の製造方法、及び新規なペンタフルオロスルファニルベンゼン化合物
JP5439745B2 (ja) * 2008-05-27 2014-03-12 宇部興産株式会社 ハロゲノメチルペンタフルオロスルファニルベンゼン化合物及びその製造方法
US9102608B2 (en) 2011-12-06 2015-08-11 Ube Industries, Ltd. Method for producing pentafluorosulfanyl benzoic acid
CN108003034B (zh) * 2017-12-26 2020-07-03 金凯(辽宁)化工有限公司 一种2-甲基-5-氨基三氟甲苯的制备方法
RU2765117C2 (ru) * 2019-09-24 2022-01-25 Федеральное государственное автономное образовательное учреждение высшего образования "Уральский федеральный университет имени первого Президента России Б.Н. Ельцина" Применение натриевой соли диэтилового эфира 4-оксо-1,4-дигидропиразоло[5,1-с]-1,2,4-триазин-3,8-дикарбоновой кислоты, моногидрата в качестве средства лечения и профилактики поздних осложнений сахарного диабета

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4417004A1 (de) * 1994-05-13 1995-11-16 Hoechst Ag Perfluoralkyl-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19517848A1 (de) * 1995-05-16 1996-11-21 Merck Patent Gmbh Fluorhaltige Benzoylguanidine
DE19526381A1 (de) * 1995-07-19 1997-01-23 Hoechst Ag 4-Fluoralkyl-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
GB9606015D0 (en) * 1996-03-22 1996-05-22 Rhone Poulenc Agriculture New herbicides

Also Published As

Publication number Publication date
MA27277A1 (fr) 2005-04-01
NO20045447L (no) 2004-12-14
NO333288B1 (no) 2013-04-29
PT1509498E (pt) 2007-01-31
RS50772B (sr) 2010-08-31
AU2003242531A1 (en) 2003-12-02
ZA200408886B (en) 2006-01-25
CN1653044A (zh) 2005-08-10
IL165213A0 (en) 2005-12-18
RS99004A (en) 2007-04-10
EP1509498A1 (de) 2005-03-02
HK1076095A1 (en) 2006-01-06
CA2486336A1 (en) 2003-11-27
MY139310A (en) 2009-09-30
RU2315752C2 (ru) 2008-01-27
RU2004137115A (ru) 2005-05-27
IL165213A (en) 2009-05-04
ATE343563T1 (de) 2006-11-15
KR20040111635A (ko) 2004-12-31
TWI281467B (en) 2007-05-21
BR0311128A (pt) 2005-03-08
TW200407290A (en) 2004-05-16
PL371784A1 (en) 2005-06-27
PL209700B1 (pl) 2011-10-31
JP4383341B2 (ja) 2009-12-16
HRP20041078B1 (hr) 2013-02-28
JP2005526138A (ja) 2005-09-02
EP1509498B1 (de) 2006-10-25
WO2003097591A1 (de) 2003-11-27
MXPA04011497A (es) 2005-02-14
DE10222192A1 (de) 2003-11-27
CY1105867T1 (el) 2011-02-02
AR040034A1 (es) 2005-03-09
CA2486336C (en) 2011-06-21
ES2274264T3 (es) 2007-05-16
DK1509498T3 (da) 2007-02-26
DE50305498D1 (de) 2006-12-07
MEP28908A (en) 2010-10-10
AU2003242531B2 (en) 2008-07-31
HRP20041078A2 (en) 2005-04-30
KR100977676B1 (ko) 2010-08-25
CN100506791C (zh) 2009-07-01

Similar Documents

Publication Publication Date Title
PE20040452A1 (es) Pentafluorosulfanilbenzoilguanidinas como inhibidores del nhe
PE20040559A1 (es) Benzoilguanidinas cicloalquilderivadas fluoradas, procedimiento para su preparacion y medicamentos que las contienen
PE20050036A1 (es) COMPUESTOS DE FENIL-AZA-BENZIMIDAZOL PARA MODULAR LA IgE E INHIBIR LA PROLIFERACION CELULAR
MEP61208A (en) Novel compounds having inhibitory activity against sodium-dependant transporter
CY1119039T1 (el) Mykhtoktonikh συνθεση και μεθοδος για ελεγχο επιβλαβων μυκητων
PE20030086A1 (es) Derivados de acidos tiofen dicarboxilicos como inhibidores de histona desacilasa (hdca)
PE20010211A1 (es) Compuestos de tiazol y composiciones farmaceuticas para inhibir las quinasas de proteina
SE0300956D0 (sv) Stabilisatorblandningar
AR009519A1 (es) Compuesto analogo de carbazol, formulacion farmaceutica que lo comprende y su uso para fabricar un medicamento.
ECSP045472A (es) "derivados de n-((3-oxo-2,3-dihidro-1h-isoindol-1-il)acetil)guanidina en calidad de inhibidores de nhe-1 para el tratamiento del infarto y la angina de pecho"
AR052866A1 (es) Fenil-metanonas monociclicas sustituidas
BR9907962A (pt) Composição farmacêntica, composto, e, processo para preparar o mesmo
PE20011066A1 (es) PIRIDO [2,3-d] PIRIMIDIN-2,7-DIAMINAS INHIBIDORES DE CINASAS
RU2003108857A (ru) Гидроксаматные производные, применимые в качестве ингибиторов дезацетилазы
PE20121148A1 (es) Compuestos heterociclicos y usos de los mismos
ATE277012T1 (de) Piperidin- und pyrrolidin-derivate enthaltend ein stickstoffoxid donor zur behandlung von stress
CO5090835A1 (es) Biciclo [2.2.1] heptanos y compuestos relacionados
PE20050130A1 (es) Compuestos organicos
PE20120024A1 (es) DERIVADOS DE LA PIRIDINA SUSTITUIDO CON ANILLO HETEROCICLICO Y GRUPO y- GLUTAMINICO, Y AGENTES ANTIFUNGALES QUE LOS CONTIENEN
PE20080136A1 (es) Arilsulfonamidas sustituidas como agentes antivirales
ATE318260T1 (de) Stabilisatormischung
PE20071089A1 (es) Compuesto heterociclico fusionado como inhibidor de tirosina quinasa
CO6150089A2 (es) Nuevas amidas de acido quinoliniloxialcanoico, procesos de obtencion y composiciones que las contienen
BRPI0412285A (pt) os compostos de quinazolinona substituìda por arilamina
PE20060384A1 (es) Derivados de acido benzoico como inhibidores no nucleosidos de la transcriptasa inversa

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed